Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroscience
Pharma
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.
Angus Liu
Apr 23, 2025 10:35am
Even through its remake, Alkermes retains upward trajectory: CEO
Jan 13, 2025 7:36am
A revival in neuro therapeutics
Oct 11, 2024 8:37am
BMS wins FDA approval for new schizophrenia med Cobenfy
Sep 26, 2024 7:38pm
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
JPM24: Alkermes ready to roll as pure-play neuroscience company
Jan 10, 2024 9:04am
